GROWTH HORMONE AXIS / FAQ
Questions From the Trial Record
Direct, citation-anchored answers to the questions readers most often bring to these three growth-hormone-axis research peptides.
What is CJC-1295 / Ipamorelin good for?
CJC-1295/Ipamorelin is a combination of a long-acting GHRH analogue (CJC-1295) and a selective ghrelin-receptor agonist (ipamorelin), studied — separately, not as a fixed blend — for stimulating the body's own growth-hormone release. CJC-1295 alone has been shown to raise GH two- to ten-fold and IGF-1 for over a week after a single dose in healthy adults [3], and cell-based work shows the two components' receptors work together to roughly double the resulting cAMP signal compared with GHRH-receptor activation alone [5]. No controlled human trial has tested what the fixed combination itself is good for as an outcome measure — claims about the specific combination's real-world benefits come from research-community reports, not clinical trials, and are anecdotal, not clinical evidence.
What are the bad side effects of CJC-1295 and Ipamorelin?
The best-documented class-level concern for GH secretagogues broadly is a modest rise in blood glucose from reduced insulin sensitivity [2]. Research-use communities frequently report mild injection-site redness or swelling, transient water retention, a brief facial flush after dosing, and occasional tingling or grogginess — reports that are anecdotal, not clinical evidence, since no controlled trial has evaluated the combination's side-effect profile directly. Because CJC-1295 raises GH and IGF-1 for extended periods [3], the mitogenic (cell-growth-promoting) nature of those hormones is a mechanistic, class-level caution for anyone with active or recent malignancy, though this has not been studied specifically for the blend.
How long do CJC-1295 and Ipamorelin take to work?
The two components act on very different timescales, which is itself a caution rather than a simple answer. Ipamorelin alone produces a short GH pulse that resolves within hours. CJC-1295 with DAC, by contrast, raised GH for six or more days and IGF-1 for nine to eleven days after a single dose in healthy adults, with repeated dosing keeping IGF-1 elevated for up to 28 days [3]. Because no trial has tested the combination as a fixed protocol, how quickly a combined effect appears — or how long it is sustained — has not been formally measured; community timelines describing week-by-week benefits are anecdotal, not clinical evidence.
How many mg of CJC-1295 and Ipamorelin should I take?
This desk does not recommend a dose for any individual — that is a clinical decision outside what a literature digest can responsibly answer. What can be reported factually is that no controlled human trial has established a dosing protocol for the fixed CJC-1295 + ipamorelin combination at all. The published human pharmacology comes from single-agent studies: a single subcutaneous dose of CJC-1295 (DAC) in healthy adults, for instance, produced multi-day elevations in GH and IGF-1 [3]. Describing what a study dose did is not the same as recommending a dose for anyone, and no research-community protocol for the combined product has been evaluated for safety in a controlled setting.
What is sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide that reproduces the amino-terminal fragment of human growth hormone-releasing hormone (GHRH) — the shortest fragment known to retain full activity at the GHRH receptor. It signals the pituitary gland to release the body's own growth hormone rather than supplying growth hormone directly. It was originally FDA-approved as an injectable therapy for pediatric growth-hormone deficiency, under a branded formulation withdrawn from the market in 2008 for commercial reasons, and is available today through compounding pharmacies [6][9].
What does sermorelin do to the body?
Sermorelin binds GHRH receptors on pituitary somatotroph cells, triggering the cAMP/protein kinase A pathway that drives synthesis and pulsatile release of growth hormone (GH). The released GH then stimulates the liver to produce IGF-1, the hormone responsible for much of GH's downstream effect on muscle, fat, and connective tissue. Because sermorelin acts upstream of GH itself, the body's natural feedback loop — which normally reins the signal back in — stays intact, distinguishing it mechanistically from direct GH replacement [6][9].
Does sermorelin work?
The honest answer depends on the outcome and the population. In prepubertal children with confirmed growth-hormone deficiency, daily GHRH(1-29) reliably accelerated linear growth in controlled trials [10]. In healthy older men, twice-daily dosing reversed age-related declines in GH and IGF-1 to youthful levels over two weeks [12]. For the broader modern uses it is marketed for — anti-aging, general body composition, wellness — the evidence is thinner, and a widely cited editorial concluded that using GH secretagogues for aging is 'not yet ready for prime time' [8]. So it demonstrably raises GH and IGF-1 as intended; whether that translates into a specific desired outcome depends heavily on which outcome and which population is being asked about.
How long does it take for sermorelin to work?
In controlled trials, measurable hormonal changes appear quickly — intravenous GHRH(1-29) triggered significant GH release within the same session at doses as low as 0.25 mcg/kg [11], and two weeks of twice-daily dosing was enough to normalize GH and IGF-1 levels in older men [12]. Research-community reports describe a much slower subjective timeline for sleep, energy, or body-composition changes — often calling the first month a 'slow burn' with more noticeable effects only in the second or third month — but that timeline is anecdotal, not clinical evidence, since it has not been measured in a controlled trial.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of the complete human growth hormone-releasing hormone (GHRH), chemically modified with a trans-3-hexenoic acid group that resists breakdown by the enzyme DPP-IV. It is the only compound on this desk with a current FDA approval — specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a fat-redistribution condition linked to certain antiretroviral treatments [13].
What does tesamorelin do?
Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile release of the body's own growth hormone, which in turn drives hepatic IGF-1 production and lipolysis with a documented preference for visceral (deep abdominal) fat. In its pivotal 24-week trial, tesamorelin produced a treatment effect of -42 cm2 in visceral fat and reduced hepatic fat content by a net -2.9% compared with placebo [14]. A 52-week extension found the visceral-fat reduction sustained at -18% versus baseline, though fat reaccumulated after the drug was stopped [16].
How does tesamorelin work?
By activating the Gs/adenylyl-cyclase/cAMP pathway at the GHRH receptor, tesamorelin drives the pituitary to release growth hormone in its normal pulsatile pattern, rather than delivering GH directly. GH then stimulates the liver to produce IGF-1, and the two hormones together promote fat breakdown, preferentially from visceral fat depots. In healthy men, two weeks of tesamorelin measurably raised overnight GH and IGF-1 without significantly affecting fasting glucose or insulin-stimulated glucose uptake — an early signal that its metabolic profile differs from direct growth-hormone administration [15].
Will tesamorelin help me lose belly fat?
Tesamorelin's FDA approval and its strongest trial evidence apply specifically to reducing visceral (deep abdominal) fat in people with HIV-associated lipodystrophy — a specific fat-redistribution condition, not general belly fat in the broader population. In that studied population, tesamorelin produced statistically significant, sustained reductions in visceral fat over as long as 52 weeks, with fat reaccumulating once treatment stopped [14][16]. Whether that effect generalizes to people without HIV-associated lipodystrophy has not been established by the same level of randomized-trial evidence, and this desk does not offer guidance on individual use — that is a question for a licensed clinician.